T 1127/05 (Inhibition of angiogenesis/SCRIPPS RESEARCH INSTITUTE) 15-01-2008

Reasons for the Decision

Claim format - First or Second Medical Use

1. An issue in the present case is whether the EPC 1973 or EPC 2000 version of Article 54(5) applies to the European patent application in question.

2. Article 1, point 3 of the Decision of the Administrative Council of 28 June 2001 on the transitional provisions under Article 7 of the Act Revising the EPC of 29 November 2000 ("Transitional Decision") states:

"Article 54(5) [of EPC 2000] shall apply to European patent applications pending at the time of its entry into force, in so far as a decision on the grant of the patent has not yet been taken".

3. The decision of the Examining Division was to refuse to grant a patent. From Article 106 EPC the effect of the appellant's appeal is to suspend this decision, thus the appellant's European patent application remains pending and is thus a "European patent application(s) pending at the time of its [the EPC 2000] entry into force" within the meaning of Article 1, point 3 of the Transitional Decision.

4. A question arises, however, as to the meaning of "...a decision on the grant of the patent..". In English this has two meanings as a "decision on the grant" can be either a positive decision to grant the patent, or a negative decision to refuse to grant a patent. The French and German versions of Article 1, point 3 of the Transitional Decision are similarly ambiguous.

5. By referring to the travaux préparatoires of the Transitional Decision which are found in the document CA/PL 3/01 Rev. 1 of 4 May 2001, "Revisions of the EPC: transitional provisions", this ambiguity can be resolved. Point 9 of this document states:

"Article 1, point 3, of the draft decision [that is of what became Article 1, point 3 of the Transitional Decision (board's remark)] provides for the new Article 54(5) to be applied to pending applications in cases where the decision on the grant of the European patent (Article 97(2), Rule 51(11) EPC) has not yet been taken at the time of entry into force of the revised version. This prevents the new provision from being applied to proceedings which have already been concluded, while at the same time ensuring that pending applications, as well as later applications, can benefit from purpose-related substance protection for further medical uses".

6. Article 1, point 3 of the draft Transitional Decision that is annexed as part II of document CA/PL 3/01 Rev. 1 of 4 May 2001 is identical to Article 1, point 3 of the Transitional Decision except that the first words of the draft version read "Article 54(5) shall be applied also to European patent applications...", whereas the final version reads "Article 54(5) shall apply to European patent applications...". This does not appear to be a material difference in what concerns the present discussion.

7. The above reference in document CA/PL 3/01 Rev. 1 of 4 May 2001 to "Article 97(2), Rule 51(11) EPC" is a reference to Article 97(2) and Rule 51(11) EPC 1973. This is clear from first, the wording surrounding this reference to the EPC which refers to a time prior to the entry into force of the EPC 2000, and second, from the fact that it is only in the EPC 1973 that Rule 51(11) exists.

The relevant text of Article 97(2) EPC 1973 is:

"If the Examining Division is of the opinion that the application and the invention to which it relates meet the requirements of this Convention, it shall decide to grant the European patent for the designated Contracting states..."

The text of Rule 51(11) EPC 1973 is:

"The decision to grant the European patent shall state which text of the European patent application forms the basis for the grant of the European patent".

Thus the "decision on grant" referred to in Article 1, point 3 of the Transitional Decision is clearly a decision to grant a patent.

8. In this case the decision of the examining division was to refuse to grant a patent, thus within the sense of Article 1, point 3 of the Transitional Decision, no decision on the grant of a patent has been taken and thus Article 54(5) EPC applies to the present application.

Amendments

9. The board is satisfied that the amendment in claim 1 now reciting "inhibiting alphanybeta3-mediated angiogenesis in a tissue" (emphasis added) derives from the application as a whole and in particular the passage at page 110 of the application as filed, lines 26 to 29 referring to inhibiting alphanybeta3-mediated angiogenesis as described in example 11.

10. The amendment in claim 3, now stipulating that the claimed antagonist is for inhibiting the growth of the solid tumor, is based on the wording of claim 29 as originally filed (see section I).

11. Accordingly the amendments to the claims comply with the requirements of Article 123(2) EPC.

Novelty

12. The board agrees with the examining division and the appellant that document (2) is contained in the state of the art by virtue of the undisputed lack of entitlement of the patent application, insofar as it concerns the compounds of the Main Request, to the priority date.

13. Document (2) discloses that, under physiological conditions, angiogenesis - a process of tissue vascularisation that involves the growth of new developing blood vessels into a tissue, also known as neo-vascularisation - "is highly regulated and has been shown to be activated by specific angiogenic cytokines such as basic fibroblast growth factor (bFGF) and tumor necrosis factor-alpha (TNF-alpha). As described by Brooks ..., monoclonal antibodies against alphanybeta3 have been shown to block both bFGF- and TNF-alpha induced angiogenesis in model systems including the CAM model described below. As described in examples 4-6, monoclonal antibodies against alphanybeta5 block a separate pathway of angiogenesis, specifically that induced by vascular endothelial growth factor (VEGF), transforming growth factor TGF-alpha and epidermal growth factor (EGF)." (page 47, line 26 to page 48, line 2; emphasis added). The document continues that "in the context of the present invention, two pathways of angiogenesis are defined by distinct integrins, alphanybeta3 and alphanybeta5.". Accordingly, and this is also confirmed by document (1), two distinct pathways for angiogenesis were known in the prior art each mediated by different integrins. Specific monoclonal antibodies to either of the integrins alphanybeta3 and alphanybeta5 could inhibit alphanybeta3- and alphanybeta5-meditiated angiogenesis, respectively.

Document (2) furthermore discloses various groups of alphanybeta5 antagonists which can act as inhibitors of alphanybeta5-meditiated angiogenesis, i.e. the previously referred to alphanybeta5 monoclonal antibodies, linear or cyclic peptides or proteins and organic molecules which are mimetics of the alphanybeta5 ligand, also referred to as an organic mimetic, all of which specifically interact with alphanybeta5 (see page 8, lines 13 to 24).

Example 10 of document (2) discloses the "Preparation of Organic Molecule alphanybeta5 Antagonists", which according to the title of the section on page 41, line 20 to page 42, line 11 of the document are "alphanybeta5-specific mimetics". The compounds disclosed as organic mimetic compounds 7, 9, 10, 12 or 14 are identical to the organic mimetic compound having a structure according to formula 7, 9, 10, 12 or 14 as claimed in claim 1.

14. It has not been contested by the appellant that document (2) discloses the organic mimetic compound having a structure according to formula 7, 9, 10, 12 or 14 as claimed in claim 1 and their use in inhibiting (alphanybeta5-mediated) angiogenesis. Accordingly, the provision of Article 54(4) EPC, which stipulates that the provisions of its paragraphs (2) and (3) shall not exclude the patentability of any substance comprised in the state of the art, for use in a method referred to in Article 53(c) EPC, provided that its use for any such method is not comprised in the state of the art, can not provide novelty for the subject-matter of claim 1.

15. Article 54(5) EPC on the other hand provides that the provisions of Article 54(2) and (3) EPC shall not exclude the patentability of any substance referred to in Article 54(4) EPC for any specific use in a method referred to in Article 53(c) EPC, provided that such use is not comprised in the state of the art.

It therefore needs to be determined whether the use of known organic compounds in the inhibition of alphanybeta3-mediated angiogenesis, as claimed, is such a specific use that was not comprised in the state of the art.

16. Document (2) does not disclose, either explicitly or implicitly, the use of the organic mimetics for the inhibition of alphanybeta3-mediated angiogenesis. The achievement of this technical effect is however a technical feature of claim 1.

17. Document (1) at page 1502 (left-hand column, first full paragraph) discloses that angiogenesis is a common pathological feature of most ocular diseases that cause catastrophic loss of vision and notes that although ischemia-associated retinal neovascular diseases such as proliferative diabetic retinopathy are associated with increased VEGF, nonischemic retinal neovascular diseases such as age related macular degeneration have no such clear association. Accordingly, the fact that VEGF-stimulated (i.e. alphanybeta5-meditiated) angiogenesis proceeded by an intergrin-mediated angiogenic pathway distinct from that stimulated by FGF (i.e. alphanybeta5-mediated) angiogenesis supports the inference that different pathogenetic mechanisms may operate in retinal and subretinal angiogenesis related diseases.

18. The board concludes from the above referred to disclosure in document (1) that alphanybeta3- and alphanybeta5-mediated angiogenesis are associated with different diseases. Accordingly, the inhibition of alphanybeta3-mediated angiogenesis by the organic mimetic compound having a structure according to formula 7, 9, 10, 12 or 14 as claimed in claim 1 is a specific use as compared to their use in the inhibition of angiogenesis in general or the inibition of alphanybeta5-mediated angiogenesis which was not comprised in the state of the art.

19. The examining division has argued that the present application discloses that the claimed compounds, which were known to be alphanybeta5 antagonists, are also inhibitors of alphanybeta3-mediated angiogenesis. Since the use of the compounds in the treatment of angiogenesis was thus known in the prior art, the mechanism by which said angiogenesis was inhibited, either by alphanybeta3 or alphanybeta5 receptors, (i.e. both from document (2)) could not confer novelty to the claimed medical application.

20. The board cannot concur with the finding of the examining division. Certain examples of document (2) refer in a general manner to the use of the "alphanybeta5-specific mimetics" as claimed in various experiments modulating angiogenesis. Example 6.C and 6.D describe the use of the organic molecules in tumor-induced angiogenesis (see in particular page 64, lines 19 to 23 and page 65, lines 16 to 24). Example 8 discloses a SCID/human chimeric model involving solid human M21L human melanoma cell line tumors on human skin grafts on SCID mice. On page 68, lines 2 to 11, intraperitonal use of the alphanybeta5 antagonist peptide 189 was reported to result in a significant reduction of the tumor volume. The claimed compounds were reported also to have been tested for their effectiveness as alphanybeta5 antagonist in the above model (page 68, lines 12 to 15). Example 9 discloses inhibition of angiogenesis in a murine retinal angiogenesis model by a alphanybeta5 antagonsist (cyclic peptide). Also here the assays were reported to have performed with the claimed compounds (page 70, lines 4 to 5).

21. The board notes that from document (2) itself it is not disclosed whether the process for the inhibition of angiogenesis, besides being alphanybeta5-mediated, is also alphanybeta3-mediated. The fact that the claimed compounds can block both angiogenesis pathways in the same tissue may inherently be disclosed in document (2). However, the board refers to point 12 above, in which it was concluded that that alphanybeta3- and alphanybeta5-mediated angiogenesis are associated with different diseases. The claimed compounds in their application of alphanybeta3-mediated angiogenesis inhibitors open up new areas of therapeutic treatment.

22. In view of the above considerations and in following principles established in the decision G 5/83 of the Enlarged Board of Appeal (OJ EPO, 1985, 4), the subject matter of claim 1 of the Main Request is novel (Article 54 EPC). Since the dependent claims concern specific embodiments falling within the scope of independent claim 1, the subject-matter of these claims is also novel.

Procedural point

23. The decision of the examining division was solely based on the finding that the subject-matter of claim 1 before them lacked novelty over the disclosure in document (2). In order not to deprive the appellant of the two instance procedure established under the EPC for the consideration of objections to the grant of a patent, the board considers it appropriate to exercise its discretion under Article 111(1) EPC by remitting the case to the first instance for further prosecution.